Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)
Parque Empresarial Las Mercedes
Edificio 8
C/ Campezo, 1
E - 28022 Madrid
Spain
(Reference Member State)

MUTUAL RECOGNITION PROCEDURE

PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

Caliermutin 800 mg/g premix for pigs (ES, PT)

MODULE 1

PRODUCT SUMMARY

EU Procedure number	ES/V/0117/003/X/001
Name, strength and pharmaceutical form	Caliermutin 800 mg/g premix for pigs (ES, PT)
Applicant	Laboratorios Calier, S.A. C/Barcelonés, 26 (Plá del Ramassá) 08520 Les Franqueses del Vallés Barcelona-España
Active substance(s)	Tiamulin hydrogen fumarate
ATC Vetcode	QJ 01 XX 92
Target species	Pigs
Indication for use	Treatment and prevention of swine dysentery induced by *B. hyodysenteriae* Treatment of enzootic pneumonia induced by *M. hyopneumoniae.*

MODULE 2

The Summary of Product Characteristics (SPC) for this product is available on the Heads of Medicines Agencies (veterinary) (HMA(v) website) (www.HEVRA.org).

MODULE 3

PUBLIC ASSESSMENT REPORT

Legal basis of original application	Mutual Recognition application in accordance with Article 12 of Directive 2001/82/EC as amended.
Date of completion of the original mutual recognition procedure	25th September 2013
Date product first authorised in the Reference Member State (MRP only)	5th February 2010
Concerned Member States for original procedure	Portugal

I. SCIENTIFIC OVERVIEW

For public assessment reports for the first authorisation in a range:

The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.
It has been shown that the product can be safely used in the target species; the slight reactions observed are indicated in the SPC.
The product is safe for the user, the consumer of foodstuffs from treated animals and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.
The efficacy of the product was demonstrated according to the claims made in the SPC.
The overall risk/benefit analysis is in favour of granting a marketing authorisation.

II. QUALITY ASPECTS

A. Composition

The product contains as active substance Tiamulin hydrogen fumarate (800 mg) (An overdose of tiamulin hydrogen fumarate 5% is done, so 840, 0 mg/ 1g of tiamulin hydrogen fumarate are measured out).
Excipients are: Carmellose sodium and lactose monohydrate.

The container/closure system is 25 kg polyethylene bags as a primary packaging and cardboard drums of 25 kg as a secondary packaging.

The particulars of the containers and controls performed are provided and conform to the regulation.

The pharmaceutical development is well documented. It justifies the chosen formulation and the manufacturing method to produce a homogeneous and stable premix, suitable for the proposed use.

B. Method of Preparation of the Product

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site. A flow chart is enclosed in the dossier. The manufacturing equipment is detailed. The manufacturing process has been described.
Process validation data on the product have been presented in accordance with the relevant European guidelines in three pilot batches. Analysis certificates of three pilot batches and the three first commercial batches also support the suitability of the process to produce a homogeneous premix with a consistent quality.

C. Control of Starting Materials

The active substance is Tiamulin hydrogen fumarate, an established active substance described in the European Pharmacopoeia (01/2008:1659 corrected 6.0). The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

The applicant justifies the quality of the raw material by means of a Certificate of Suitability CEP nº R1-CEP 2005-169-Rev 00 (18/12/12).

Carmellose sodium, lactose monohydrate, and purified water comply with the monographs number Eur.Ph 01/2008:0472 corrected 6.0, Eur.Ph 07/2009:0187 and Eur.Ph 01/2009:0008 of the European Pharmacopoeia, respectively. Certificates of analysis are submitted.

D. Specific Measures concerning the Prevention of the Transmission of Animal Spongiform Encephalopathies

Documentation from the suppliers to justify that starting materials have no risk of transmitting BSE are included.

E. Control on intermediate products

It is considered as intermediate product, each of the two batches of Tiamulin HF 80% granulate which are mixed to prepare the product. Content on Tiamulin hydrogen fumarate and particle size are routinely controlled for release of this intermediate product.

F. Control Tests on the Finished Product

The routine controls have been considered enough for the proposed use of the finished product (medicated premix). In general, they have been designed according to procedures of the European pharmacopoeia. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.

Satisfactory validation data for the analytical methods have been provided.

Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification.

G. Stability

The Certificate of Suitability CEP nº R1-CEP 2005-169-Rev 00 (18/12/12) for Tiamulin hydrogen fumarate provide a shelf life of 3 years

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life (24 months) without any specific condition of storage.

The Applicant did not include information on a shelf life period once opened the package. So, a warning of do not store the product in this condition was added to the SPC.

Stability studies according to the guideline EMEA/CVMP/080/95 “Additional quality requirements for products intended for incorporation into animal feedingstuffs” to justify a validity period of the product when incorporated to feed are presented up to 3 months.

III. SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL)

III.A Safety Testing

Pharmacological Studies

Pharmacodynamics:

Pharmacokinetics:

Toxicological Studies

Observations in Humans

Microbiological Studies

User Safety

Ecotoxicity

III.B Residues documentation

Residue Studies

MRLs

Withdrawal Periods

.

IV. CLINICAL ASSESSMENT (EFFICACY)

IV.A Pre-Clinical Studies (pharmaceuticals only)

Pharmacology (if relevant – or delete)

Tolerance in the Target Species of Animals

Resistance *(if relevant – or delete)*

IV.B Clinical Studies (pharmaceuticals and immunologicals)

Field trials

V . OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.